

MPAC meeting 10- 12 September 2014

Declaration of Interests

All MPAC members participating in the meeting updated their declaration of interest, which was assessed by the WHO Secretariat.

Nine members reported relevant interests, which are summarized below. It was concluded that all members could take part in full in all of the discussions.

Salim Abdulla

Is director of the Ifakara Health Institute, which receives research funding from MVI and MMV. This interest was assessed as non-personal, non-specific and financially significant*.

Fred Binka

Receives research support from the Bill & Melinda Gates Foundation. This interest was assessed as non-personal, non-specific and financially significant*.

Brian Greenwood

Receives research funding from the Malaria Vaccine Initiative for the RTS,S vaccine trial. This interest was assessed as non-personal, non-specific, and financially significant*.

Rose Leke

Receives funding from Pfizer and the National Institute of Allergy and Infectious Diseases (NIAID), USA. This interest was assessed as non-personal, non-specific and financially significant*.

Kevin Marsh

Is on the malaria vaccines advisory group for USAID, is a PI on the Phase 3 RTS,S study and a collaborator on a Phase 2 malaria vaccine study. This interest was assessed as non-personal, non-specific, and financially significant*.

Sylvia Meek

Is technical director of the Malaria Consortium which receives research funding from the Bill & Melinda Gates Foundation, DfID, and CDC. This interest was assessed as being non-personal, non-specific, and financially significant*.

Allan Schapira

Received consultancy fees from GH Tech, World Bank, and UNDP. This interest was assessed as being personal, non-specific, and financially significant*.

Marcel Tanner

Directs the Swiss Tropical and Public Health Institute which receives research funding from Novartis Institute for Tropical Diseases, SNF, Wellcome Trust, Malaria Vaccine Initiative and the Bill & Melinda Gates Foundation. This interest was assessed to be non-personal, non-specific, and financial significant*.

Neena Valecha

Directs the National Institute of Malaria Research - New Delhi, which receives research funding from companies: BASF, Sumitomo, Vestergaard, Bayer, and Syngenta. This interest was assessed to be non-personal, non-specific and financially significant*.

*According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single malaria-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one malaria-related company in excess of 1,000 USD would also constitute a "significant shareholding".